CJC-1295 vs Ipamorelin: GHRH vs GHRP Comparison

CJC-1295 and Ipamorelin are both growth hormone secretagogues, but they act on different receptors: CJC-1295 is a GHRH analog that primes the pituitary through the GHRH receptor, while Ipamorelin is a highly selective ghrelin-receptor (GHS-R1a) agonist that triggers the actual GH pulse. Because their mechanisms are complementary rather than competing, they are most often researched together as a stack, not as substitutes for one another. Neither is FDA-approved.

Side-by-Side Comparison

Parameter	CJC-1295	Ipamorelin
Class	GHRH analog	Pentapeptide GHRP / selective ghrelin-receptor agonist
Mechanism	GHRH receptor (GHRHR) agonist; primes pituitary somatotrophs via Gs-cAMP-PKA signaling, does not itself trigger GH release	GHS-R1a (ghrelin receptor) agonist; directly triggers GH exocytosis via IP3/calcium signaling
Evidence Grade	B+	A-
Route	Subcutaneous injection	Subcutaneous injection
Typical Dose	No DAC: 100-300 mcg, 2-3x daily. DAC: 2 mg, once weekly or every 2 weeks	100-300 mcg per administration; ~1 mcg/kg is near-maximal (dose ceiling)
Half-Life	No DAC: ~30 minutes. DAC: 6-8 days	~2 hours
FDA Status	Not approved; research compound	Not approved; research compound
Selectivity	Does not directly trigger GH release; primes receptor sensitivity only	Highly selective — GH release without meaningfully raising cortisol, prolactin, or ACTH, even at doses far above the GH-effective range
Reported Side Effects	Injection-site reactions; DAC variant may blunt natural pulsatile GH architecture with continuous use	Generally well-tolerated at research doses; mild water retention or injection-site reactions reported
Storage	Refrigerate 2-8°C reconstituted; protect from light	Refrigerate 2-8°C reconstituted; protect from light

CJC-1295: Pros & Cons

Advantages

DAC variant allows once-weekly dosing convenience
No DAC variant preserves natural pulsatile GH architecture when dosed correctly
Primes the pituitary, amplifying the effect of a GHRP/GHSR agonist when stacked
Grade B+ human pharmacokinetic and GH-stimulation data

Considerations

Does not directly trigger a GH pulse on its own — priming effect is smaller alone than when stacked
DAC variant's sustained elevation may blunt pulsatile GH release over time
Two distinct variants (DAC vs no DAC) with very different half-lives and dosing schedules can confuse protocol design

Ipamorelin: Pros & Cons

Advantages

Most selective GH secretagogue studied — minimal cortisol/prolactin/ACTH effect
Grade A- evidence, considered a reference standard for selective GH secretion research
Clean, well-characterized dose-response relationship with a natural dose ceiling
Simpler single-variant dosing compared to CJC-1295's DAC/no-DAC split

Considerations

Short ~2-hour half-life requires multiple daily doses for sustained research protocols
Triggers GH release but does not prime the pituitary the way a GHRH analog does — smaller pulse amplitude alone than when stacked with CJC-1295
Dose ceiling around 1 mcg/kg limits how much a single dose can be scaled up

Which Is Right for Your Research?

Decision Guide

Choose CJC-1295 alone if: The research question is specifically about GHRH-receptor priming or sustained GH elevation (DAC variant), independent of a ghrelin-pathway trigger.

Choose Ipamorelin alone if: The research priority is the cleanest possible GH pulse with minimal off-target hormonal activity, without needing a GHRH-priming component.

Stack them if: This is by far the most studied approach for either compound. CJC-1295 no DAC + Ipamorelin (commonly 100 mcg + 100-200 mcg, injected together, fasted) is the reference GHRH/GHSR combination — GHRH priming plus GHSR triggering produces a GH pulse larger than either compound alone, without meaningfully worsening either compound's already-favorable side-effect profile. See the CJC-1295 + Ipamorelin stack protocol for the combined dosing approach.

Frequently Asked Questions

Can I use CJC-1295 without Ipamorelin?▼

Yes. CJC-1295 alone still elevates GH by priming pituitary somatotrophs through the GHRH receptor, and CJC-1295 DAC in particular produces sustained GH elevation on its own. Used without a GHRP/GHSR agonist like Ipamorelin, the GH pulse amplitude is generally smaller than the combined stack, but it is a valid standalone research protocol.

Do I need to inject CJC-1295 and Ipamorelin separately?▼

They are commonly drawn into the same syringe and injected together since both are typically dosed subcutaneously at the same frequency (CJC-1295 no DAC + Ipamorelin, both fasted, often pre-bed). CJC-1295 DAC, which is dosed weekly rather than daily, is more often run on its own schedule rather than combined into daily Ipamorelin injections.

Is CJC-1295 or Ipamorelin better for a cleaner side-effect profile?▼

Ipamorelin is the more selective of the two on its own, producing GH release without meaningfully raising cortisol, prolactin, or ACTH. CJC-1295 no DAC has a comparatively clean profile as well since it doesn't directly trigger the ghrelin-receptor pathways associated with appetite/cortisol effects in other GHRPs. Combining the two doesn't meaningfully worsen either compound's side-effect profile, which is part of why the stack is popular.

Related Protocol Guides

CJC-1295 Overview CJC-1295 No DAC Protocol CJC-1295 DAC Protocol Ipamorelin Overview Ipamorelin Protocol CJC-1295 + Ipamorelin Stack Ipamorelin vs Sermorelin CJC-1295 vs Sermorelin

Verified Research Suppliers

Research-grade peptides are available from verified suppliers listed on our Vendor Comparison page. All listed vendors meet cGMP certification and third-party testing standards.

Related Tools & Resources

Peptide vs Peptide Compare Compounds Effect Matrix Dosing Calculator Interaction Checker